Free Trial
Earnings Season Is Here. MarketBeat All Access for Just $149
Get the Deal
Claim MarketBeat All Access Sale Promotion
NASDAQ:CDXS

Codexis Q3 2026 Earnings Date & Estimates

Codexis logo
$1.29 -0.03 (-2.27%)
As of 10:27 AM Eastern

Codexis is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. The conference call is scheduled for 4:30 PM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
After Market Closes
Conference Call
4:30 PM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Codexis in Q3 2026

Codexis is expected to post earnings of -$0.09 per share on revenue of $18.73 million. In the same quarter a year earlier Codexis reported -$0.22 per share on revenue of $8.60 million. Codexis last reported on August 11, 2026, posting -$0.13 per share and beating the -$0.1417 consensus estimate. Codexis has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.09
Expected Revenue
$18.73 million
Prior-Year EPS
-$0.22
Prior-Year Revenue
$8.60 million
Expected Revenue Growth
+117.7%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.13 (Beat by +$0.0117)
Last Quarter Revenue
$14.92 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Codexis Q3 2026 Earnings FAQ

Codexis (NASDAQ:CDXS) is estimated to report Q3 2026 earnings on Thursday, November 5, 2026, after market closes. This date is estimated from past reporting schedules and may change once the company confirms it.

Codexis' Q3 2026 earnings conference call is scheduled for Thursday, November 5, 2026 at 4:30 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Codexis to post earnings of -$0.09 per share for Q3 2026.

The consensus revenue estimate for Codexis is $18.73 million for Q3 2026.

Codexis Earnings Headlines

Codexis Partners With SiRNA Drug Developer To Advance Next-Generation RNA Manufacturing
September 28, 2026  |  rttnews.comhttps://www.rttnews.com/3694440/codexis-partners-with-sirna-drug-developer-to-advance-next-generation-rna-manufacturing.aspx
Codexis partners with siRNA drug innovator for enzymatic oligonucleotide synthesis
September 28, 2026  |  msn.comhttps://www.msn.com/en-us/news/other/codexis-partners-with-sirna-drug-innovator-for-enzymatic-oligonucleotide-synthesis/ar-AA2d7rkZ
Trump’s Plan To Cheat History
China has slashed its U.S. Treasury holdings by more than 45% from their peak, while building gold vaults and payment networks that bypass the dollar entirely. Since the Federal Reserve opened in 1913, the dollar has lost most of its purchasing power. Porter Stansberry argues a new monetary order is forming around AI infrastructure, chips and energy, pointing to stocks like Vertiv, GE Vernova and Arista Networks that have surged hundreds of percent in recent years.tc pixel
October 20 at 1:00 AM  |  Porter & Company (Ad)
Codexis Enters into an Agreement with Pioneering siRNA Drug Innovator to Leverage the ECO Synthesis Manufacturing Platform to Create Stereo-defined siRNA
September 28, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/28/3369692/24825/en/codexis-enters-into-an-agreement-with-pioneering-sirna-drug-innovator-to-leverage-the-eco-synthesis-manufacturing-platform-to-create-stereo-defined-sirna.html
Codexis to Participate in Cantor Global Healthcare Conference 2026
August 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/27/3352067/24825/en/codexis-to-participate-in-cantor-global-healthcare-conference-2026.html
Codexis Earnings Call: Margin Gains, Scale-Up Bets
August 19, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/codexis-earnings-call-margin-gains-scale-up-bets?utm_source=marketbeat.com&utm_medium=referral
See More Codexis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email.

About Codexis

Codexis (NASDAQ:CDXS) is a biotechnology company that develops enzyme-based technologies and biocatalysts for pharmaceutical, life sciences and industrial applications. Its technology is designed to help customers produce complex molecules more efficiently, with potentially improved selectivity, productivity and sustainability compared with conventional chemical manufacturing methods.

The company’s core technology platform, CodeEvolver, uses protein engineering, data science and laboratory methods to develop enzymes with specific performance characteristics. Codexis provides engineered enzymes and related solutions for applications including the manufacture of active pharmaceutical ingredients, pharmaceutical intermediates, nucleic acid components and other high-value chemicals.

Codexis was founded in 2002 and is headquartered in Redwood City, California. The company works with customers and partners internationally, serving pharmaceutical and other life sciences markets as well as selected industrial and specialty-chemical applications. Its business includes both the development of customized enzyme solutions and the commercialization of enzyme products.

Stephen Dilly serves as Codexis’ president and chief executive officer. The company’s shares trade on the Nasdaq under the symbol CDXS.

View Codexis Profile
Earnings Tools